Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cropropamide SCHEMBL25324 | 0.95 | — | — | |
| Crotetamide SCHEMBL26013 | 0.92 | CYP3A4 (0.33) | CYP3A4LMNA | |
| Crotetamide SCHEMBL26015 | 0.92 | CYP3A4 (0.33) | CYP3A4LMNA | |
| SCHEMBL18699228 | 0.68 | CYP3A4 (0.39) | CYP3A4LMNA | |
| SCHEMBL24859121 | 0.66 | CASP1 (0.40) | CYP3A4LMNA | |
| SCHEMBL28176134 | 0.66 | CASP1 (0.40) | CYP3A4LMNA | |
| SCHEMBL22053010 | 0.65 | CYP3A4 (0.40) | CYP3A4LMNA | |
| SCHEMBL9113596 | 0.64 | CA12 (0.41) | CYP3A4LMNA | |
| SCHEMBL21078225 | 0.64 | TSHR (0.36) | LMNA | |
| SCHEMBL6636617 | 0.64 | CA12 (0.44) | CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008033351-A2 | MULTIMODAL ABUSE RESISTANT AND EXTENDED RELEASE FORMULATIONS | THERAQUEST BIOSCIENCES, INC. (US) | 2008-03-20 | — | — | WO | claimed |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ENALARE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | ENALARE THERAPEUTICS INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250325554-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS | ENALARE THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250262218-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR STIMULATING RESPIRATION | Auros Pharma LLC | 2025-08-21 | — | — | US | disclosed |
| WO-2023225177-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS | ENALARE THERAPEUTICS INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20220241268-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ENALARE THERAPEUTICS INC. | 2022-08-04 | — | — | US | disclosed |
| WO-2020236975-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | PERGOLIZZI JOSEPH V (US) | 2020-11-26 | — | — | WO | disclosed |
| US-9802937-B2 | Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-10-31 | — | — | US | disclosed |
| US-9642809-B2 | Controlled release pharmaceutical compositions for prolonged effect | EGALET LTD. (GB) | 2017-05-09 | — | — | US | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2012143143-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012143144-A1 | PYRAZOLO [4, 3-D] PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
| US-20100239667-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | EGALET A/S (DK) | 2010-09-23 | — | — | US | disclosed |
| EP-2155167-A2 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | Egalet A/S (DK) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008148798-A2 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | EGALET A/S (DK) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008033351-A2 | MULTIMODAL ABUSE RESISTANT AND EXTENDED RELEASE FORMULATIONS | THERAQUEST BIOSCIENCES, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-4448776-A | Method of using certain substituted aliphatic secondary amines or their salts for easing breathing | BUCHER KARL (CH) | 1984-05-15 | — | — | US | disclosed |
| US-4029789-A | ANTIASTHMA, ANTIULCER | DELALANDE S.A. (FR) | 1977-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544369-B2 | Methods and pharmaceutical compositions to treat drug overdose | OPRK1, OPRD1, OPRM1 | CYP3A4 106/4885LMNA 1240/4885 |
| US-20260137675-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | ADRA2B, ADRB1, ADRB2 | CYP3A4 101/4885LMNA 499/4885 |
| US-20250325554-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT RESPIRATORY DEPRESSION IN PATIENTS | NDUFB6, NDUFB7, CHRM5 | CYP3A4 991/4885LMNA 1470/4885 |
| US-20220241268-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS TO TREAT DRUG OVERDOSE | OPRK1, OPRM1, ADRB1 | CYP3A4 160/4885LMNA 390/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | CYP3A4 4198/4885LMNA 3015/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | CYP3A4 4807/4885LMNA 3020/4885 |
| US-20100239667-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS FOR PROLONGED EFFECT | SI, GIPR, MLN | CYP3A4 1467/4885LMNA 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.